Research graph
References from Nectin-4-Directed Therapeutic Repositioning Augments Antitumor Efficacy in Epithelial Ovarian Carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer
10.1056/nejmoa2309169 · 2023 · External reference
Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA Study
10.1200/jco.22.01900 · 2023 · External reference
10.1038/s41568-026-00916-0
10.1038/s41568-026-00916-0 · External reference
Enfortumab vedotin in previously treated advanced urothelial carcinoma
10.1056/nejmoa2035807 · 2021 · External reference
Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models
10.1158/0008-5472.can-15-1313 · 2016 · External reference
10.1038/s41568-021-00388-4
10.1038/s41568-021-00388-4 · External reference
10.1038/s41416-019-0650-z
10.1038/s41416-019-0650-z · External reference
10.1038/s41571-021-00470-8
10.1038/s41571-021-00470-8 · External reference
10.1158/2767-9764.crc-24-0093
10.1158/2767-9764.crc-24-0093 · External reference
10.1158/2767-9764.crc-24-0435
10.1158/2767-9764.crc-24-0435 · External reference
